<DOC>
	<DOC>NCT00787137</DOC>
	<brief_summary>The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis. The secondary objectives are to evaluate how PG102 moves around the body and to explore its effects on the disease.</brief_summary>
	<brief_title>Single Dose PG102 in Patients With Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Arthritis that meets Classification of Psoriatic Arthritis (CASPAR) criteria Plaque psoriasis for at least 6 months prior to study enrollment Clinically significant psoriasis flare Unstable doses of pain relief medication Treatment with systemic corticosteroids other than prednisone ≤ 10 mg/day or equivalent Treatment with any biologic therapy Treatment with immunosuppressive agents or disease modifying antirheumatic drugs (DMARDs) other than methotrexate Treatment with lithium, any antimalarial, chlorambucil, cyclophosphamide or therapies for psoriasis other than low potency topical corticosteroids on intertriginous and groin areas, tar or salicylate preparations on the scalp, and emollients and moisturisers Family history of multiple thrombotic events or a personal history of any venous or arterial thrombotic event Clinically significant result for anticardiolipin, Activated protein C resistance test, Protein C, Free Protein S, Antithrombin III, Factor V Leiden, Prothrombin variant, Homocysteine, Lupus anticoagulant, Prothrombin time, Activated partial thromboplastin time, Fibrinogen, Thrombin time, Factors IX and XI Currently smoking ≥ 10 cigarettes per day or equivalent Active tuberculosis or other infection Current or previous malignancies Clinically significant abnormality on physical examination, laboratory testing, vital signs or 12lead electrocardiogram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>